Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering

June 13, 2019

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome,  announced on 6/12/19 that it is commencing an underwritten registered public offering of $60.0 million of shares of its common stock. As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Seres.

Seres lead candidate, SER-109, is in Ph III trials. SER-109 is being developed as a treatment for C. difficle. The company is also developing products for ulcerative colitis and for use in combination with immuno-oncology treatments. The company expects to file an IND for one of its potential UC treatments (SER-301) by early 2020. Seres intends to use the net proceeds of this offering to  advance the development of our product candidates and for other general corporate and working capital purposes.




CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.